1.0Impact Factor
2.0CiteScore
34 daysTime to First Decision

Hemato, Volume 3, Issue 2

June 2022 - 6 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (6)

Select all

Article

2,556 Views

12 Pages

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors

Tatsuki Shibuta,
Honoka Shimizu,
Yukichi Takada,
Asuka Fuku,
Satoshi Tomiyasu and
Tsukuru Umemura

Hemato2022, 3(2), 373-384;https://doi.org/10.3390/hemato3020026

13 June 2022

Extracellular vesicles (EVs) are nano-sized particles released from cells and transferring molecules (proteins, lipids and nucleic acids such as mRNA, tRNA and miRNA) to recipient cells. Surface antigens and components are important for the functions...

Full Article

Article

2,654 Views

6 Pages

Histological Kidney Re-Evaluation after Daratumumab Monotherapy for AL Amyloidosis

Roberta Fenoglio,
Gianluca Rabajoli,
Antonella Barreca,
Emanuele De Simone,
Savino Sciascia and
Dario Roccatello

Hemato2022, 3(2), 367-372;https://doi.org/10.3390/hemato3020025

13 June 2022

Background: AL amyloidosis is a systemic disorder characterized by extracellular deposition of characteristic fibrils that results in progressive multi-organ failure and premature death. Recently daratumumab has been demonstrating higher hematologica...

Full Article

Feature Paper
Review

46 Citations

50,657 Views

26 Pages

Sickle Cell Disease, a Review

Cameron K. Tebbi

Hemato2022, 3(2), 341-366;https://doi.org/10.3390/hemato3020024

30 May 2022

Sickle cell disease and its variants constitute the most common inherited blood disorders affecting millions of individuals worldwide. Significant information regarding the nature of the genetic mutations and modifier genes that result in increased o...

Full Article

Review

10 Citations

10,328 Views

23 Pages

Primary Cutaneous B-Cell Lymphoma: An Update on Pathologic and Molecular Features

Marco Lucioni,
Sara Fraticelli,
Giuseppe Neri,
Monica Feltri,
Giuseppina Ferrario,
Roberta Riboni and
Marco Paulli

Hemato2022, 3(2), 318-340;https://doi.org/10.3390/hemato3020023

29 May 2022

Primary cutaneous B-cell lymphomas (PCBCLs) account for 25% of all primary cutaneous lymphomas. Three major types are currently recognized by the WHO classification: primary cutaneous marginal zone B-cell lymphoma (PCMZL), primary cutaneous follicle...

Full Article

Review

1 Citations

3,829 Views

20 Pages

Laboratory-Based Rationale for Targeting the Protein Homeostasis Network in AL Amyloidosis

Giada Bianchi,
Maria Moscvin and
Raymond L. Comenzo

Hemato2022, 3(2), 298-317;https://doi.org/10.3390/hemato3020022

25 April 2022

AL amyloidosis is an incurable plasma cell dyscrasia with limited therapeutic options. The pathogenetic mechanism in AL amyloidosis is the deposition of insoluble fibrillary aggregates of misfolded immunoglobulin (Ig) free light chains (FLC) and chap...

Full Article

Feature Paper
Review

1 Citations

4,580 Views

11 Pages

What Is Genomic High-Risk Myeloma?

Faith E. Davies and
Brian A. Walker

Hemato2022, 3(2), 287-297;https://doi.org/10.3390/hemato3020021

5 April 2022

Although treatment of multiple myeloma has changed dramatically over time, there is still a subpopulation of patients who do not respond to treatments and are labeled as high risk. A combination of serum and genomic markers can be used to identify an...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Hemato - ISSN 2673-6357

Imprint

Download Flyer